"HIV Cure" 101 Workshop Current Community Questions and Concerns about “HIV Cure” Bill Whittaker National Association of People with HIV Australia.

Slides:



Advertisements
Similar presentations
Diseases without borders What must the Global Development Community Do? World Bank Seminar Series Tawhid Nawaz, Operations Advisor Human Development Network.
Advertisements

PEPFAR’s Approach to Maximize Efficiency, Effectiveness and Impact
Giving us a global voice Cecilia Chung, USA On behalf of the Key Populations Living with HIV Advisory Group of GNP+
REPORT HIGHLIGHTS “Children should be the first to benefit from our successes in defeating HIV, and the last to suffer from our failures.” Anthony Lake,
Key Policy Issues: 2013 Pan-African Parliament / UNAIDS Dialogue Pride Chigwedere, MD, PhD Senior Advisor, UNAIDS Liaison Office to the AU.
Pharmaceuticals and Global Health: Successes, Challenges and Outlook 19. July 2013, University of Sussex Thomas B. Cueni, Secretary General Interpharma.
GENERATING DEMAND FOR DATA Module 1. Session Objectives  Understand the importance of improving data-informed decision making  Understand the role of.
Almost 14 years ago all countries endorsed a set of 8 Millennium Development Goals (or MDGs). 3 of those 8 Goals focus on health – that being child mortality,
Technical Advisory Group meeting, WHO/WPRO
Modeling Studies in AIDS Vaccine R&D 1 Arne Naeveke Executive Director Advocacy, Policy and Communications IAEN – AIDS 2014 Pre-conference – July 19, 2014,
Sustaining Local Public Health and Built Environment Programs Fit Nation NYC November 3, 2011 Annaliese Calhoun.
Global Health Program Guiding Principles April 2002.
Toward a Broader Vision of Sexual Health in the New Millennium Eli Coleman, PhD Academic Chair in Sexual Health Professor and Director Program in Human.
Outcomes of Public Health
TITLE from VIEW and SLIDE MASTER | 27 July 2006 AID EFFECTIVENESS FOR HEALTH: TOWARDS THE 4TH HIGH-LEVEL FORUM, BUSAN AID EFFECTIVENESS FOR HEALTH.
Partnerships in Promoting Innovation and Managing Risk Scientific and Financial Innovation in AIDS Vaccines International AIDS Vaccine Initiative Labeeb.
Community Issues And Needs Associated With Microbicides Clinical Trials Presenter: John M. Mutsambi, Community Liaison Officer with University of Zimbabwe.
IAS 2012 feedback: UK Consortium: September 2012 IAS 2012 Feedback: New findings, better drugs and the goal of a cure Simon Collins HIV.
T HE M ULTISECTORAL A PPROACH, I NVESTMENT T HINKING AND N ATIONAL AIDS R ESPONSE C OORDINATION M ESFIN G ETAHUN & B ENJAMIN O FOSU -K ORANTENG N OVEMBER.
DR CHIDI V NWENEKA EXECUTIVE DIRECTOR AFRICAN AIDS VACCINE PARTNERSHIP AAVP and the Promotion of HIV Vaccines in Africa: Supporting Career Development.
National Malaria Program Scale-up for Advocacy Based on Impact 23 January 2006.
Learning journey Part 1: Welcome and introduction Part 2: Concepts, evidence, and good practice: Addressing gender-based violence and engaging men and.
Joan Holloway Vice President, Global Health Initiatives Multidisciplinary Care Team Delivery of Integrated HIV Services.
Enabling Continuity of a Public Health ARV Treatment program in a resource limited setting: The Case of the transition of the African Comprehensive HIV/AIDS.
ETHICS AND INFORMED CONSENT FOR HIV CURE RESEARCH david evans project inform ETHICS AND INFORMED CONSENT FOR HIV CURE RESEARCH david evans project inform.
Benefits of building the HIVe Why build the HIVe? How to build the HIVe Results of building the HIVe.
D.Zucker Draft-EB09 Ethics & Academic Technology Transfer: Patients, Products and Public Trust Deborah Zucker, MD, PhD, Tufts Medical Center.
Monitoring UA 2010 in health sector 1 |1 | Monitoring progress towards Universal Access 2010 in the health sector Kevin M De Cock Ties Boerma.
19-20 JULY 2012 WASHINGTON D.C Community Mobilization & Activism Community Mobilization & Activism.
Building a Microbicides Movement Partnerships in advocacy and science. Global Campaign for Microbicides.
Gender Equality and Country Dialogues: Zimbabwe’s Experience with NFM Tendai F Mhaka Zimbabwe GES Workshop Jakarta 3 March 2014.
Principles and Practices: The implementation of ethical guidelines for research on HIV Geneva, 2-3 June 2003 Ethical guidelines for HIV vaccines: Generic.
The AIDS Vaccine Policy Agenda Holly J. Wong Vice President, Public Policy International AIDS Vaccine Initiative (IAVI) Vienna, Austria International AIDS.
IAS Policy and Advocacy priority on Treatment as Prevention Carlos F. Cáceres Multidisciplinary Research on ARV-based Prevention 30 June 2013 Kuala Lumpur.
Mysoltani.ir سایت فیلم روشهای مشارکتی Technology Foresight Foresight is about preparing for the future. It is about deploying resources in the best.
Western Cape Wellness Summit 08 November 2011 Infectious Diseases.
XVII INTERNATIONAL AIDS CONFERENCE PANCAP Satellite Meeting Hon Douglas Slater, Minister of Health, St. Vincent and the Grenadines.
Malaria Eradication: Ethics, Autonomy, Priorities David Brandling-Bennett Deputy Director, Malaria Infectious Diseases, Global Health Program May 3, 2011.
The Millennium Development Goals The fight against global poverty and inequality.
Prevention of HIV infection: How effectively are countries responding to changing epidemics in the Asia Pacific Region? 1.
OVERVIEW OF MACROECONOMIC & HEALTH KEY POINTS FROM THE OCTOBER 2003 GLOBAL CONSULTATION Briefing for Permanent Mission Representatives.
TB/HIV Working Group Working Groups Collaboration to Raise and Enhance Awareness of TB/HIV Colleen Daniels Technical Officer TB/HIV Advocacy & Communications.
The Australian Government’s Overseas Aid Program © Commonwealth of Australia 2003 Australia’s International Development Strategy for HIV Intensifying the.
Global Advocacy “Towards an HIV Cure” Marie-Capucine Penicaud, IAS Community Scientific Literacy Workshop July 22, 2012.
5-6-1 Unit 6: Ethical considerations After completing this unit, you should be able to: Understand the basic ethical principles of working with.
Pharmacovigilance in HIV/AIDS Public Health Programmes: Luxury or Priority? November 2009, dar Es Salaam.
1/28/2016 Prevention Research and Natioanl Aids Plans Geneva 1 Prevention Research and National AIDS Plans June 2005 Geneva, Switzerland Prof. Roy.
Understanding the Investment Approach Faith Mamba Regional Support Team Eastern and Southern Africa.
Country and community preparedness: Community Involvement in Clinical Trials Global Campaign for Microbicides.
2014 “Towards an HIV Cure” symposium Melbourne Cure Research and the Community David Evans, Project Inform.
GLOBAL HEALTH SECURITY text Looking Ahead: Strategies for Building a Platform Pandemic Influenza Vaccines: Building a Platform for Global Collaboration.
HPTN Ethics Guidance for Research: Community Obligations Africa Regional Working Group Meeting, May 19-23, 2003 Lusaka, Zambia.
33 MEETING OF THE UNAIDS PROGRAMME COORDINATING BOARD GENEVA, SWITZERLAND DECEMBER 2013 THE EQUITY DEFICIT: UNEQUAL AND UNFAIR ACCESS TO HIV TREATMENT,
Managing adolescents and young people with HIV: Challenges and Solutions: Introduction Dr. Tajudeen Oyewale, MD, MPH, PhD. HIV Section, UNICEF New York.
2007 Pan American Health Organization 2004 Pan American Health Organization Malaria in the Americas: Progress, Challenges, Strategies and Main Activities.
Aligning Policy Agendas The case of personalised care and cure for healthy and active ageing Setting the scene for the DG Regio and Flanders Smart Specialisation.
Partners in Progress: Deciding to Participate in Parkinson’s Clinical Research.
Office of Global Health and HIV (OGHH) Office of Overseas Programming & Training Support (OPATS) What is Health? What is Public Health? Global Health Training.
SAFE toward a WORLD for children Five-Year Strategic Plan
Ladies and gentlemen, On behalf of my country, the Republic of Côte d’Ivoire, I want to tell you how very pleased I am to be part of this high-level meeting,
Overview of guidance/frameworks
We know what to do: the unfinished agenda and priority next steps
Richard hayes London school of hygiene & Tropical Medicine
Lecture 9: PHC As a Strategy For HP Dr J. Sitali
Initiatives in HIV.
Patrick Brenny, UNAIDS RST-WCA
TB HLM accountability framework
SETTING TARGETS TO DRIVE DECISIONS MAKING AND ACOUNTABILITY
A Time of Commitments and Actions to accelerate action to End TB
Dr Timothy Armstrong Coordinator
Presentation transcript:

"HIV Cure" 101 Workshop Current Community Questions and Concerns about “HIV Cure” Bill Whittaker National Association of People with HIV Australia

My take on community questions and concerns about “HIV Cure” research: How we sustain support and participation in HIV Cure Research. Researchers and Community partnerships. Global commitments to Cure. Hype and Hyperbole – media and us. Impact on current Treatment and Prevention efforts. Priority for Cure vs “Other” HIV research. Cost Effectiveness and Equity of Access. Cure research funding – pharmaceutical industry. Ethical Issues and Cure Research. Priorities for Global Response & Focus of Cure Research. “HIV Cure” – Community Questions and Concerns Today’s Talk

A long history of community participation in HIV research. Still high levels of altruism and interest in HIV research. “HIV Cure” – Community Questions and Concerns Participation in HIV Cure Research - Altruism

“HIV Cure” – Community Questions and Concerns Participation in HIV Cure Research - Altruism Survey of 2100 HIV positive people in 2011/12. Over half reported that the possibility of benefiting others would motivate them to join a trial even if there were some potential risks for them. A separate question asked about willingness to participate in studies that might advance the science but offer little prospect of individual benefit for them; 45 percent responded that they would be either willing or very willing. [Evans and Vogel TAGline Fall 2013]

Value and respect this resource of people. Ongoing support for and participation in HIV research depends on keeping the community informed. Successful research benefits from dialogue with community and involvement of advocates in planning and strategizing Cure research. “HIV Cure” – Community Questions and Concerns Participation in HIV Research - Altruism

“HIV Cure” – Community Questions and Concerns Partnering with the Community in HIV Research D.A.R.E.

“HIV Cure” – Community Questions and Concerns International Commitments – Global Cure Leadership 2011 United Nations Political Declaration on HIV Countries committed to accelerating investment in cure research. Countries committed to ensuring the highest ethical standards (DM). ?? How will countries meet these commitments & monitoring. What is the leadership and framework needed to support cure research into the future: Governments International IAS and others

Sensationalist Cure reporting, commentary, hype…… “HIV Cure” – Community Questions and Concerns Hype and Hyperbole – Media and Us. It’s not just the media! Potential to undermine prevention and current treatment programs – community awareness.

Some may hold off treating now because of cure availability. Cure may impact on prevention – biomedical and proven prevention programs. Messaging is complex today – a challenge: Rapid testing Test and Treat Treatment as Prevention PrEP Community and broader communication – sophisticated approach. “HIV Cure” – Community Questions and Concerns Impact on current Treatment and Prevention efforts

Could scientific effort, funding and focus be concentrated too narrowly? Will this be at the expense of other important research? Unlikely - cure research is not some “niche activity”. We must communicate exactly what we mean by a cure – possibilities and limitations. “HIV Cure” – Community Questions and Concerns Priority for Cure vs “Other” HIV research

“HIV Cure” – Community Questions and Concerns Cost Effectiveness and Equity of Access

Cost effectiveness – must be a critical issue for governments, regulatory agencies, pharmaceutical industry, the community and health systems. Regulatory authorities may well approve treatments which provide a cure, but the cost could make this out of reach for many. They may also approve treatments which will only work in specific populations. To end the epidemic – the “cure” is going to need to be cost-effective. “HIV Cure” – Community Questions and Concerns Cost Effectiveness and Equity of Access

“HIV Cure” – Community Questions and Concerns Cure research funding – pharmaceutical industry

“HIV Cure” – Community Questions and Concerns Ethical Issues and Cure Research Ethical issues - high priority for community. Most PWHIV doing well – low threshold for toxicities from new “cure” interventions. Ensure participants make fully informed and voluntary decisions. Developing and developed settings – differences in ethic review arrangements, regulatory authorities and support levels for research participants. What is crucial is the stuff that goes on leading up to signing the informed consent – and ongoing. Good informed consent is optimized when there is broader community awareness fostered by researchers, pharma, regulatory authorities.

“HIV Cure” – Community Questions and Concerns Priorities for Global Response & Focus of Cure Research We have the means to achieve virtual elimination of HIV and AIDS now. Achieving universal access to ART - highest priority. Cure research should focus not only on controlling or eradicating HIV – but also restoring the damage already done by HIV. Addressing the chronic immune activation and inflammation that persists with HIV, even with successful ART. A false dichotomy. In the exciting pursuit of ending AIDS and finding a cure – may a thousand research flowers bloom.

“HIV Cure” – Community Questions and Concerns